Neuclone
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4 Cornwallis St, Eveleigh, New South Wal...Phone Number
+61 292094020Website
www.neuclone.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Neuclone
NeuClone is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of high-quality biosimilar products. The company aims to increase patient access to life-saving therapies by providing affordable healthcare solutions. NeuClone focuses on creating a diverse portfolio of clinically identical biosimilars to meet global patient needs. Their commitment to quality, capacity, and cost efficiency positions them as a key player in the biosimilars market.Explore more
Neuclone Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuclone your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Neuclone has new funding data
Click to see if Neuclone had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Neuclone
Check out if Neuclone is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Neuclone recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Neuclone has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Neuclone launches new products
Neuclone, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Neuclone
Find more new buyers
Compare Similar Companies to Neuclone
Compare insights from companies similar to Neuclone, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neuclone is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Neuclone is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Neuclone.
Neuclone Tech Stack
A closer look at the technologies used by Neuclone
See more technologies
Neuclone News & Media
NeuClone Discloses Two Biosimilars Referencing Opdivo® and Keytruda®
SYDNEY--(BUSINESS WIRE)--NeuClone discloses two additional biosimilars in active development referencing Opdivo (nivolumab) and Keytruda (pembrolizumab).NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab) Biosimilar Phase I Clinical Trial
SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced successful completion of monitoring visits and blood sampling for subjects in the Phase I clinical trial for its Stelara® (ustekinumab) biosimilar candidate, NeuLara. Over 200 healthy volunteers received a single dose of either NeuLara, US-sourced Stelara®, or EU-sourced Stelara®. Each subject was monitorNeuClone Completes Dosing in Phase I Clinical Trial of Stelara® (ustekinumab) Biosimilar Candidate
SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced successful recruitment and dosing of all subjects in the Phase I clinical trial for its Stelara® (ustekinumab) biosimilar candidate, NeuLara. The final subject was dosed last week. No serious treatment related adverse events have been reported to date. A total of 210 subjects were randomized into three arNeuClone Announces Positive Results from Phase I Study of Herceptin® (Trastuzumab) Biosimilar Candidate
SYDNEY--(BUSINESS WIRE)--NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced that NeuCeptin, a biosimilar candidate of Herceptin® (trastuzumab), has successfully met all primary and secondary endpoints in a Phase I clinical trial. This includes all pre-specified criteria demonstrating clinical pharmacokinetic (PK) similarity of NeuCeptin, compared to US- and EU-sourced Herceptin®.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Neuclone
Sign Up For FreeTo access detailed company insights
NeuClone is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of high-quality biosimilar products. The company aims to increase patient access to life-saving therapies by providing affordable healthcare solutions. NeuClone focuses on creating a diverse portfolio of clinically identical biosimilars to meet... Read More
